Issue 12 | Week of 22 June 2026 No major cardiology congress fell this week, and the most consequential evidence again arrived through journal publication. A single thread ran through it: cardiology is increasingly judged not on how a therapy performs at one or two years, but on whether its advantage
Issue 11 | Week of 15 June 2026 No major cardiology congress fell this week. The most consequential evidence arrived through journal publication, and a single thread ran through it: a treatment can be mechanistically sound, biologically attractive, or statistically associated with benefit, and still fail when it is tested properly.
Issue 10 | Week of 8 June 2026 No major cardiology congress fell this week. The European Renal Association (ERA) Congress in Glasgow, from 3 to 6 June, set the agenda, with the strongest cardiorenal evidence published simultaneously in JAMA and The Lancet. Cardiology Intelligence Briefing: where evidence stops Cardiovascular medicine
Issue 9 | Week of 1 June 2026 No major general cardiology congress fell in this window, and the week's most-discussed evidence arrived mainly through journal publication, including two early-phase platform studies in the New England Journal of Medicine. Cardiology Intelligence Briefing: the distance between promise and
Issue 8 | Week of 25 May 2026 EuroPCR took place in Paris from 19 to 22 May, dominating this week's evidence with three simultaneous publications across Circulation and EuroIntervention. Cardiology Intelligence Briefing: refining what we already do The five papers this week ask a narrower but increasingly important
Issue 7 | Week of 18 May 2026 Heart Failure 2026 closed in Barcelona on 12 May. The week that followed is lighter on the congress calendar but heavier on the questions large trials are not designed to answer. Cardiology Intelligence Briefing: between the landmarks Landmark cardiovascular trials earn their authority
Issue 6 | Week of 11 May 2026 Heart Failure 2026 is taking place in Barcelona from 9 to 12 May, dominating this week's evidence with four major publications across Nature Medicine and JAMA. Cardiology Intelligence Briefing: old drugs, new evidence Heart Failure 2026 week produced an unexpected protagonist:
Issue 5 | Week of 4 May 2026 Heart Rhythm 2026 closed in Chicago on 26 April. This issue covers one trial from the meeting alongside new publications in the New England Journal of Medicine (NEJM), the Lancet, and the Journal of the American College of Cardiology (JACC). Cardiology Intelligence Briefing:
Issue 4 | Week of 27 April 2026 ESC Preventive Cardiology 2026 took place in Ljubljana from 23 to 25 April and Heart Rhythm 2026 ran in parallel in Chicago from 23 to 26 April, making this one of the busiest weeks of the year for new cardiology evidence. Cardiology Intelligence
Issue 3 | Week of 20 April 2026 EHRA 2026 took place in Paris from 12 to 14 April, dominating this week's evidence in electrophysiology and device therapy. Cardiology Intelligence Briefing: trials that clarify, rather than settle This week's trials answer questions clinicians have been deciding on
Issue 2 | Week of 13 April 2026 ACC.26 produced the most concentrated wave of practice-changing cardiology evidence so far this year. With landmark trials still being digested from the conference, this issue covers five more key papers from ACC.26, each with important implications for clinical decision-making.
Cardiology
The week's most important cardiology evidence, with an honest assessment of what should and shouldn't change your practice.